Chiasma, Inc.
https://chiasma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Chiasma, Inc.
Crinetics’ Paltusotine Future Appears Bright With First Phase III Acromegaly Readout
The once-daily oral somatostatin receptor type 2 (SST2) agonist outshined placebo in patients switching from standard of care, offering an attractive alternative to once-monthly injectables.
Analysts Impressed By Amryt As EB Drug Action Date Approaches
Amryt has set out its future plans to the investment community with much depending on the successful relaunch of its just-acquired acromegaly drug Mycapssa and a potential FDA approval for its epidermolysis bullosa gel Filsuvez.
Gilead’s Long-Acting HIV Drug Among Latest EU Filings
The European Medicines Agency has added seven new products to its list of medicines that are under review for potential EU marketing authorization.
Orphan Drugs Nefecon, Maribavir & Copanlisib Among New EU Filings
Marketing applications for two generic versions of the multiple sclerosis blockbuster, Tecfidera, are also under review by the European Medicines Agency.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Large Molecule
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice